Windtree Therapeutics, Inc.
http://www.windtreetx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Windtree Therapeutics, Inc.
As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal
The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.
ASCO Preview: Three Chinese Biotechs To Watch
BeiGene, Ascentage Pharma and I-Mab will be among the first Chinese pharma firms to report clinical trial results for their innovative drug candidates at this year’s ASCO meeting.
US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?
It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.
Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity
On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- Discovery Labs